Form 4: TuHURA Biosciences Director Robert E. Hoffman Receives Stock Options

Director Robert E. Hoffman of TuHURA Biosciences, Inc. was granted 51,275 stock options on January 2, 2025, as part of the company's Non-Employee Director Compensation Program.

Summary

• Robert E. Hoffman, a director at TuHURA Biosciences, Inc., received 51,275 stock options on January 2, 2025.
• These options were granted as part of the company's Non-Employee Director Compensation Program.
• The options have an exercise price of $4.11.
• The options vest in three equal tranches, exercisable on the first, second, and third anniversaries of the grant date.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning director and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Granting stock options to directors is a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across many industries, particularly in biotech.
• The vesting schedule of one-third per year is also a common approach to ensure long-term commitment.
• The exercise price of $4.11 is specific to TuHURA Biosciences and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and value creation.

Key Dates

Keywords

stock options, director compensation, equity, TuHURA Biosciences, Robert E. Hoffman, vesting, non-employee director